Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 12/20 | 0.42 |
| ▸ | CDK4 | P11802 | 5/20 | 0.42 |
| ▸ | INSR | P06213 | 1/20 | 0.41 |
| ▸ | CCNE1 | P24864 | 5/20 | 0.41 |
| ▸ | IGF1R | P08069 | 3/20 | 0.41 |
| ▸ | EGFR | P00533 | 1/20 | 0.40 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | CDK1 | P06493 | 2/20 | 0.39 |
| ▸ | SYK | P43405 | 2/20 | 0.39 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.39 |
| ▸ | CDK19 | Q9BWU1 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7975185 | 0.91 | INSR (0.42) | CDK2INSRIGF1REGFRERBB2 | |
| SCHEMBL7974320 | 0.89 | IGF1R (0.42) | CDK2CDK4CCNE1IGF1REGFR | |
| SCHEMBL7980921 | 0.89 | CDK2 (0.43) | CDK2CDK4CCNE1KCNH2CDK1 | |
| SCHEMBL4528687 | 0.86 | CSNK2A1 (0.42) | CDK2SYK | |
| SCHEMBL7976431 | 0.84 | CDK2 (0.42) | CDK2CDK4INSRCCNE1KCNH2 | |
| SCHEMBL7964761 | 0.84 | HDAC1 (0.48) | CDK2CDK4CCNE1KCNH2CDK1 | |
| SCHEMBL10252382 | 0.84 | CDK2 (0.42) | CDK2INSRIGF1RKCNH2CDK1 | |
| SCHEMBL7995054 | 0.83 | CDK2 (0.43) | CDK2CDK4INSRCCNE1IGF1R | |
| SCHEMBL699814 | 0.82 | CDK2 (0.51) | CDK2CDK4CCNE1IGF1RCDK1 | |
| SCHEMBL10251997 | 0.81 | CDK2 (0.45) | CDK2KCNH2CDK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8124764-B2 | Fused heterocyclyc inhibitor compounds | GILEAD SCIENCES, INC. (US) | 2012-02-28 | — | — | US | disclosed |
| US-20100029638-A1 | FUSED HETEROCYCLYC INHIBITOR COMPOUNDS | GILEAD SCIENCES, INC. | 2010-02-04 | — | — | US | disclosed |
| US-20100029638-A1 | FUSED HETEROCYCLYC INHIBITOR COMPOUNDS | GILEAD SCIENCES, INC. | 2010-02-04 | — | — | US | disclosed |
| WO-2010009155-A2 | FUSED HETEROCYCLYC INHIBITOR COMPOUNDS | GILEAD COLORADO, INC. (US) | 2010-01-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029638-A1 | FUSED HETEROCYCLYC INHIBITOR COMPOUNDS | HDAC1, HDAC11, HDAC7 | CDK2 16/4885CDK4 15/4885INSR 3091/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.